Avastin is an FDA-approved monoclonal anti-vascular endothelial growth factor (VEGF)-A antibody targeting tumor angiogenesis that has been examined and commonly adopted for the regime of recurrent ovarian cancer for the past few years [48,49,50,51]. The gene discussed is VEGFA; the disease is ovarian carcinoma.